Date:3/1/2010

cing the amount of physical servers that need to be procured and maintained, Clarian is benefiting from notable cost savings as well as "green" advantages like reduced power and cooling requirements that are critical to Clarian's long-term goals.  All of Clarian's hospitals have also noted the proven ability of the virtualized Synapse system to significantly reduce report turnaround times anywhere from one to five hours.

"Fujifilm's strategic partnership with Clarian Health, coupled with their technological foresight in the PACS arena, has provided a tremendous asset that has enabled us to achieve maximum value from this initiative," said Dave Hennon, Radiology IS Director for Clarian.  "In the few short months since our initial implementation, the advantages have already been adding up.  From the cost savings and environmental benefits to the increased efficiency of our doctors, the combined endeavor of the virtualization and business continuance plan has been a great success."

In addition to rolling out the Synapse system in a virtualized environment, Fujifilm also implemented a complete disaster recovery/business continuance plan for Clarian, something the facility did not previously have.  The entire Synapse system can be failed over to another datacenter in less than an hour, enabling the health system to provide uninterrupted care.

'/>"/>

SOURCE FUJIFILM Medical Systems USA, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. FUJIFILM Europe Teams Synapse with Matrox Xenia
2. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
3. Four Alzheimers Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation
4. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
5. Glycotex, Inc. Expands Patent Portfolio in Advanced Wound Healing Indications
6. Amerinet Awards Contract to Instrumentation Laboratory for Critical Care Portfolio
7. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
8. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
9. Sarnova Announces Acquisition of CVC, Inc. to Expand Portfolio of Specialty Medical Products
10. Pharmaron Expands Portfolio of Services with Acquisition of Bridge Laboratories China
11. LifeSync Purchases Wireless Patent Portfolio from Motorola